LIVIVO - Search results -

Search results

Result 1 - 10 of total 10

Search options

Article ; Online: Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammatory Bowel Disease and Iron Deficiency without Anaemia

Jose María Huguet / Xavier Cortés / Marta Maia Boscá-Watts / Margarita Muñoz / Nuria Maroto / Marisa Iborra / Esther Hinojosa / María Capilla / Carmina Asencio / Cirilo Amoros / Jose María Paredes

Journal of Clinical Medicine, Vol 11, Iss 2786, p

2022 Volume 2786

Abstract: Background: Iron deficiency (ID) without anaemia is a common comorbidity associated with inflammatory bowel disease (IBD) that has a negative impact on health-related quality of life (HRQoL). Methods: This multicentre, prospective, observational study ... ...

Abstract	Background: Iron deficiency (ID) without anaemia is a common comorbidity associated with inflammatory bowel disease (IBD) that has a negative impact on health-related quality of life (HRQoL). Methods: This multicentre, prospective, observational study examined the response to, safety of and impact on HRQoL of a single 500 mg dose of intravenous ferric carboxymaltose (FCM) in patients with IBD and ID without anaemia. The diagnostic criteria for ID were low serum ferritin (<30 µg/L in the absence of inflammatory activity or <100 µg/L with inflammation) and transferrin saturation index (TSAT) < 16%. The effect on iron levels and HRQoL, according to the health status questionnaires SF-12v2 and EQ-5D, was evaluated 1 month after FCM infusion in an outpatient setting. Results: Of the 105 patients who received FCM, 98 patients completed the study. After 1 month, a single dose of FCM significantly increased serum ferritin, serum iron and TSAT. Importantly, patients reported fewer ID symptoms and problems on all EQ-5D dimensions. They also had higher EQ-5D visual analogue scale and SF-12v2 scores after treatment. FCM had similar clinical effects on men and women and on patients with Crohn’s disease (n = 66) and ulcerative colitis (n = 32). Conclusion: A single dose of FCM rapidly restored iron parameters and significantly improved patients’ symptoms and HRQoL at 1 month after treatment.
Keywords	iron deficiency ; health-related quality of life ; ferric carboxymaltose ; inflammatory bowel disease ; Medicine ; R
Subject code	610
Language	English
Publishing date	2022-05-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Splanchnic Vein Thrombosis in Inflammatory Bowel Disease

Maria Puig / Helena Masnou / Francisco Mesonero / Luís Menchén / Luís Bujanda / Jesús Castro / Irene González-Partida / Raquel Vicente / Carlos González-Muñoza / Marisa Iborra / Mónica Sierra / José María Huguet / María José García / Ruth De Francisco / Francisco Javier García-Alonso / Míriam Mañosa / Eugeni Domènech / on behalf of ENEIDA-GETECCU Registry

Journal of Clinical Medicine, Vol 12, Iss 23, p

An Observational Study from the ENEIDA Registry and Systematic Review

2023 Volume 7366

Abstract: Background: Thromboembolic events are frequent among patients with inflammatory bowel disease (IBD). However, there is little information on the prevalence, features and outcomes of splanchnic vein thrombosis (SVT) in patients with IBD. Aims: To describe ...

Abstract	Background: Thromboembolic events are frequent among patients with inflammatory bowel disease (IBD). However, there is little information on the prevalence, features and outcomes of splanchnic vein thrombosis (SVT) in patients with IBD. Aims: To describe the clinical features and outcomes of SVT in patients with IBD and to perform a systematic review of these data with published cases and series. Methods: A retrospective observational study from the Spanish nationwide ENEIDA registry was performed. A systematic search of the literature was performed to identify studies with at least one case of SVT in IBD patients. Results: A new cohort of 49 episodes of SVT from the Eneida registry and 318 IBD patients with IBD identified from the literature review (sixty studies: two multicentre, six single-centre and fifty-two case reports or case series) were analysed. There was a mild predominance of Crohn’s disease and the most frequent clinical presentation was abdominal pain with or without fever followed by the incidental finding in cross-sectional imaging techniques. The most frequent SVT location was the main portal trunk in two-thirds of the cases, followed by the superior mesenteric vein. Anticoagulation therapy was prescribed in almost 90% of the cases, with a high rate of radiologic resolution of SVT. Thrombophilic conditions other than IBD itself were found in at least one-fifth of patients. Conclusions: SVT seems to be a rare (or underdiagnosed) complication in IBD patients. SVT is mostly associated with disease activity and evolves suitably when anticoagulation therapy is started.
Keywords	prevalence ; splanchnic vein thrombosis ; inflammatory bowel disease ; outcome ; Medicine ; R
Subject code	610
Language	English
Publishing date	2023-11-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Evaluation of changes in intestinal microbiota in Crohn’s disease patients after anti-TNF alpha treatment

Laura Sanchis-Artero / Juan Francisco Martínez-Blanch / Sergio Manresa-Vera / Ernesto Cortés-Castell / Marina Valls-Gandia / Marisa Iborra / Jose Maria Paredes-Arquiola / Maia Boscá-Watts / Jose Maria Huguet / Rafael Gil-Borrás / Josefa Rodríguez-Morales / Xavier Cortés-Rizo

Scientific Reports, Vol 11, Iss 1, Pp 1-

2021 Volume 11

Abstract: Abstract Intestinal dysbiosis is key in the onset and development of Crohn’s disease (CD). We evaluated the microbiota changes in CD patients before and after a six-month anti-TNF treatment, comparing these changes with the microbiota of healthy subjects. ...

Abstract	Abstract Intestinal dysbiosis is key in the onset and development of Crohn’s disease (CD). We evaluated the microbiota changes in CD patients before and after a six-month anti-TNF treatment, comparing these changes with the microbiota of healthy subjects. This prospective multicenter observational study involved 27 CD patients initiating anti-TNF treatment and 16 healthy individuals. Inflammatory activity was determined at baseline, 3 and 6 months, classifying patients into responders and non-responders. Fecal microbiota was analyzed by massive genomic sequencing thought 16S rRNA amplicon sequencing before and after six months of anti-TNF treatment. The CD cohort showed a decrease in genera of the class Clostridia, short-chain fatty acid producers, and an increase in the phylum Proteobacteria (p < 0.01) versus the healthy cohort. After anti-TNF treatment, the phylum Proteobacteria also increased in non-responders versus responders (13/27) (p < 0.005), with the class Clostridia increasing. In addition, alpha diversity increased in responders versus non-responders (p < 0.01), tending towards eubiosis. An association was found (p < 0.001) in the F.prausnitzii/E.coli ratio between responders and non-responders. The F/E ratio was the most accurate biomarker of anti-TNF response (area under the curve 0.87). Thus, anti-TNF treatment allows partial restoration of intestinal microbiota in responders and the F.prausnitzii/E.coli ratio can provide a reliable indicator of response to anti-TNF in CD.
Keywords	Medicine ; R ; Science ; Q
Subject code	610
Language	English
Publishing date	2021-05-01T00:00:00Z
Publisher	Nature Portfolio
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Impact of BMGIM Music Therapy on Emotional State in Patients with Inflammatory Bowel Disease

Vicente Alejandro March-Luján / Vicente Prado-Gascó / José María Huguet / Xavier Cortés / José María Paredes Arquiola / María Capilla-Igual / María Josefa-Rodríguez-Morales / Ana Monzó-Gallego / José Luis Platero Armero / José Enrique de la Rubia Ortí

Journal of Clinical Medicine, Vol 10, Iss 1591, p

A Randomized Controlled Trial

2021 Volume 1591

Abstract: Background. Patients with inflammatory bowel disease (IBD) have a high prevalence of emotional disturbances which worsen the symptoms of the disease. As a therapeutic alternative that is part of a comprehensive care alongside medication, the Bonny Method ...

Abstract	Background. Patients with inflammatory bowel disease (IBD) have a high prevalence of emotional disturbances which worsen the symptoms of the disease. As a therapeutic alternative that is part of a comprehensive care alongside medication, the Bonny Method of Guided Imagery and Music (BMGIM) music-assisted therapy has achieved promising emotional improvements in patients with chronic diseases. The objective of the study was to determine the impact of a treatment based on a BMGIM group adaptation on patients with inflammatory bowel disease (IBD) and their emotional state, therefore analyzing state of mind, quality of life, anxiety, depression, immunocompetence as a marker of well-being, and levels of acute and chronic stress. Methods. Longitudinal, prospective, quantitative, and experimental study including 43 patients with IBD divided into an intervention group (22 patients), who received eight sessions over eight weeks, and a control group (21 patients). A saliva sample was taken from each patient before and after each session in order to determine cortisol and IgA levels. Similarly, a hair sample was taken before the first and after the last session to determine the cumulative cortisol level. All molecules were quantified using the ELISA immunoassay technique. In addition, patients completed several emotional state questionnaires: HADS, MOOD, and CCVEII. Results. An improvement was observed in the following states of mind: sadness, fear, anger, and depression. No significant effect was observed in state of mind in terms of happiness or anxiety, in the levels of cortisol in hair, and in patients’ perceived quality of life. A reduction in cortisol was observed in saliva, although this did not significantly affect the IgA titer. Conclusions. BMGIM seems to improve the emotional state of patients with IBD.
Keywords	inflammatory bowel disease ; music therapy ; guided imagery ; emotional aspects ; anxiety ; depression ; Medicine ; R
Subject code	610
Language	English
Publishing date	2021-04-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Zollinger-Ellison syndrome

Carlos Alventosa-Mateu / Luis Ferrer-Barceló / Jose María Huguet-Malavés / Luis Ferrer-Arranz / Ana Monzó-Gallego / Enrique Medina-Chuliá

Revista Espanola de Enfermedades Digestivas, Vol 105, Iss 10, Pp 640-

2013 Volume 642

Keywords	Medicine ; R ; Internal medicine ; RC31-1245 ; Specialties of internal medicine ; RC581-951 ; Diseases of the digestive system. Gastroenterology ; RC799-869
Publishing date	2013-12-01T00:00:00Z
Publisher	The Spanish Society of Digestive Pathology
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Nationwide COVID-19-EII Study

Yamile Zabana / Ignacio Marín-Jiménez / Iago Rodríguez-Lago / Isabel Vera / María Dolores Martín-Arranz / Iván Guerra / Javier P. Gisbert / Francisco Mesonero / Olga Benítez / Carlos Taxonera / Ángel Ponferrada-Díaz / Marta Piqueras / Alfredo J. Lucendo / Berta Caballol / Míriam Mañosa / Pilar Martínez-Montiel / Maia Bosca-Watts / Jordi Gordillo / Luis Bujanda /

Noemí Manceñido / Teresa Martínez-Pérez / Alicia López / Cristina Rodríguez-Gutiérrez / Santiago García-López / Pablo Vega / Montserrat Rivero / Luigi Melcarne / Maria Calvo / Marisa Iborra / Manuel Barreiro de-Acosta / Beatriz Sicilia / Jesús Barrio / José Lázaro Pérez / David Busquets / Isabel Pérez-Martínez / Mercè Navarro-Llavat / Vicent Hernández / Federico Argüelles-Arias / Fernando Ramírez Esteso / Susana Meijide / Laura Ramos / Fernando Gomollón / Fernando Muñoz / Gerard Suris / Jone Ortiz de Zarate / José María Huguet / Jordina Llaó / Mariana Fe García-Sepulcre / Mónica Sierra / Miguel Durà

Journal of Clinical Medicine, Vol 11, Iss 421, p

Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

2022 Volume 421

Abstract: We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA ... ...

Abstract	We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March–July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8–27 and 4.5, 95% CI: 1.3–15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3–11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.
Keywords	COVID-19 ; SARS-CoV-2 ; inflammatory bowel disease ; Medicine ; R
Subject code	610
Language	English
Publishing date	2022-01-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Collagenous sprue

Carlos Alventosa Mateu / Laura Larrey Ruiz / Maria Dolores Pérez Zahonero / Atilio Javier Navarro Gonzales / Pilar Canelles Gamir / José María Huguet Malavés / María Soledad Luján Sanchís / Miguel Ángel Martorell Cebollada / Enrique Medina Chuliá

Revista de Gastroenterologia del Peru, Vol 34, Iss 4, Pp 333-

secondary or independent from celiac disease?

2014 Volume 337

Abstract: Collagenous sprue is a rare disease that goes with persistent diarrhea, weight loss and bad absortion, because it affects the small intestine, mainly duodenum and proximal jejunum. Diagnosis is made by having clinical signs and histological proof of ... ...

Abstract	Collagenous sprue is a rare disease that goes with persistent diarrhea, weight loss and bad absortion, because it affects the small intestine, mainly duodenum and proximal jejunum. Diagnosis is made by having clinical signs and histological proof of atrophy and subepitelial deposit of collagenous material. Its etiology is not known completely, it is proposed that the origin is autoimmune because its relationship with celiac disease. Also there is a proposal that is a celiac evolution to gluten free diet. Is because this is not clear that we present a case of a patient with bad absorptive diarrhea and a clinical expression of collagenous sprue, that had a great clinical response to corticosteroids (prednisone) but we had to add azatioprine. Also, initially improved with home parenteral nutrition center.
Keywords	Esprúe colágeno ; Enfermedad celíaca ; Enfermedades del colágeno ; Diseases of the digestive system. Gastroenterology ; RC799-869 ; Specialties of internal medicine ; RC581-951 ; Internal medicine ; RC31-1245 ; Medicine ; R
Subject code	610
Language	Spanish
Publishing date	2014-10-01T00:00:00Z
Publisher	Sociedad de Gastroenterología del Perú
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease

María José García / Montserrat Rivero / José Miranda-Bautista / Iria Bastón-Rey / Francisco Mesonero / Eduardo Leo-Carnerero / Diego Casas-Deza / Carmen Cagigas Fernández / Albert Martin-Cardona / Ismael El Hajra / Nerea Hernández-Aretxabaleta / Isabel Pérez-Martínez / Esteban Fuentes-Valenzuela / Nuria Jiménez / Cristina Rubín de Célix / Ana Gutiérrez / Cristina Suárez Ferrer / José María Huguet / Agnes Fernández-Clotet /

María González-Vivó / Blanca Del Val / Jesús Castro-Poceiro / Luigi Melcarne / Carmen Dueñas / Marta Izquierdo / David Monfort / Abdel Bouhmidi / Patricia Ramírez De la Piscina / Eva Romero / Gema Molina / Jaime Zorrilla / Cristina Calvino-Suárez / Eugenia Sánchez / Andrea Nuñez / Olivia Sierra / Beatriz Castro / Yamile Zabana / Irene González-Partida / Saioa De la Maza / Andrés Castaño / Rodrigo Nájera-Muñoz / Luis Sánchez-Guillén / Micaela Riat Castro / José Luis Rueda / José Manuel Benítez / Pedro Delgado-Guillena / Carlos Tardillo / Elena Peña / Santiago Frago-Larramona / María Carmen Rodríguez-Grau

Journal of Clinical Medicine, Vol 10, Iss 4402, p

A Multicentre Study of Geteccu

2021 Volume 4402

Abstract: Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of ... ...

Abstract	Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered “exposed”. The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2–2.0), urgent surgery (OR: 1.6; 95% CI: 1.2–2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1–1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3–2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97–1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03–2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.
Keywords	inflammatory bowel disease ; Crohn’s disease ; ulcerative colitis ; anti-TNF ; ustekinumab ; vedolizumab ; Medicine ; R
Language	English
Publishing date	2021-09-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

María Chaparro / Iria Baston-Rey / Estela Fernández Salgado / Javier González García / Laura Ramos / María Teresa Diz-Lois Palomares / Federico Argüelles-Arias / Eva Iglesias Flores / Mercedes Cabello / Saioa Rubio Iturria / Andrea Núñez Ortiz / Mara Charro / Daniel Ginard / Carmen Dueñas Sadornil / Olga Merino Ochoa / David Busquets / Eduardo Iyo / Ana Gutiérrez Casbas / Patricia Ramírez de la Piscina /

Marta Maia Boscá-Watts / Maite Arroyo / María José García / Esther Hinojosa / Jordi Gordillo / Pilar Martínez Montiel / Benito Velayos Jiménez / Cristina Quílez Ivorra / Juan María Vázquez Morón / José María Huguet / Yago González-Lama / Ana Isabel Muñagorri Santos / Víctor Manuel Amo / María Dolores Martín Arranz / Fernando Bermejo / Jesús Martínez Cadilla / Cristina Rubín de Célix / Paola Fradejas Salazar / Antonio López San Román / Nuria Jiménez / Santiago García-López / Anna Figuerola / Itxaso Jiménez / Francisco José Martínez Cerezo / Carlos Taxonera / Pilar Varela / Ruth de Francisco / David Monfort / Gema Molina Arriero / Alejandro Hernández-Camba / Francisco Javier García Alonso / Manuel Van Domselaar / Ramón Pajares-Villarroya / Alejandro Núñez / Francisco Rodríguez Moranta / Ignacio Marín-Jiménez / Virginia Robles Alonso / María del Mar Martín Rodríguez / Patricia Camo-Monterde / Iván García Tercero / Mercedes Navarro-Llavat / Lara Arias García / Daniel Hervías Cruz / Sebastian Kloss / Alun Passey / Cynthia Novella / Eugenia Vispo / Manuel Barreiro-de Acosta / Javier P. Gisbert

Journal of Clinical Medicine, Vol 11, Iss 15, p

2022 Volume 4518

Abstract: Ustekinumab has shown efficacy in Crohn’s Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. ... ...

Abstract	Ustekinumab has shown efficacy in Crohn’s Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position this drug in the therapeutic paradigm of CD and generate hypotheses for future trials. The objective of this analysis was to determine whether baseline patient characteristics are predictive of remission and the drug durability of ustekinumab, and whether its positioning with respect to prior use of biologics has a significant effect after correcting for disease severity and phenotype at baseline using interpretable machine learning. Patients’ data from SUSTAIN, a retrospective multicenter single-arm cohort study, were used. Disease phenotype, baseline laboratory data, and prior treatment characteristics were documented. Clinical remission was defined as the Harvey Bradshaw Index ≤ 4 and was tracked longitudinally. Drug durability was defined as the time until a patient discontinued treatment. A total of 439 participants from 60 centers were included and a total of 20 baseline covariates considered. Less exposure to previous biologics had a positive effect on remission, even after controlling for baseline disease severity using a non-linear, additive, multivariable model. Additionally, age, body mass index, and fecal calprotectin at baseline were found to be statistically significant as independent negative risk factors for both remission and drug survival, with further risk factors identified for remission.
Keywords	Crohn’s Disease ; ustekinumab ; predictive factors ; Medicine ; R
Subject code	610
Language	English
Publishing date	2022-08-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain

María Chaparro / Ana Garre / Andrea Núñez Ortiz / María Teresa Diz-Lois Palomares / Cristina Rodríguez / Sabino Riestra / Milagros Vela / José Manuel Benítez / Estela Fernández Salgado / Eugenia Sánchez Rodríguez / Vicent Hernández / Rocío Ferreiro-Iglesias / Ángel Ponferrada Díaz / Jesús Barrio / José María Huguet / Beatriz Sicilia / María Dolores Martín-Arranz / Xavier Calvet / Daniel Ginard /

Inmaculada Alonso-Abreu / Luis Fernández-Salazar / Pilar Varela Trastoy / Montserrat Rivero / Isabel Vera-Mendoza / Pablo Vega / Pablo Navarro / Mónica Sierra / José Luis Cabriada / Mariam Aguas / Raquel Vicente / Mercè Navarro-Llavat / Ana Echarri / Fernando Gomollón / Elena Guerra del Río / Concepción Piñero / María José Casanova / Katerina Spicakova / Jone Ortiz de Zarate / Emilio Torrella Cortés / Ana Gutiérrez / Horacio Alonso-Galán / Álvaro Hernández-Martínez / José Miguel Marrero / Rufo Lorente Poyatos / Margalida Calafat / Lidia Martí Romero / Pilar Robledo / Orencio Bosch / Nuria Jiménez / María Esteve Comas / José María Duque / Ana María Fuentes Coronel / Manuela Josefa Sampedro / Eva Sesé Abizanda / Belén Herreros Martínez / Liliana Pozzati / Hipólito Fernández Rosáenz / Belén Crespo Suarez / Pilar López Serrano / Alfredo J. Lucendo / Margarita Muñoz Vicente / Fernando Bermejo / José Joaquín Ramírez Palanca / Margarita Menacho / Amalia Carmona / Raquel Camargo / Sandra Torra Alsina / Nuria Maroto / Juan Nerín de la Puerta / Elena Castro / Ignacio Marín-Jiménez / Belén Botella / Amparo Sapiña / Noelia Cruz / José Luis F. Forcelledo / Abdel Bouhmidi / Carlos Castaño-Milla / Verónica Opio / Isabel Nicolás / Marcos Kutz / Alfredo Abraldes Bechiarelli / Jordi Gordillo / Yolanda Ber / Yolanda Torres Domínguez / María Teresa Novella Durán / Silvia Rodríguez Mondéjar / Francisco J. Martínez-Cerezo / Lilyan Kolle / Miriam Sabat / Cesar Ledezma / Eduardo Iyo / Óscar Roncero / Rebeca Irisarri / Laia Lluis / Isabel Blázquez Gómez / Eva María Zapata / María José Alcalá / Cristina Martínez Pascual / María Montealegre / Laura Mata / Ana Monrobel / Alejandro Hernández Camba / Luis Hernández / María Tejada / Alberto Mir / María Luisa Galve / Marta Soler / Daniel Hervías / José Antonio Gómez-Valero / Manuel Barreiro-de Acosta / Fernando Rodríguez-Artalejo / Esther García-Esquinas / Javier P. Gisbert / on behalf of the EpidemIBD study group of GETECCU

Journal of Clinical Medicine, Vol 10, Iss 2885, p

Large-Scale Epidemiological Study

2021 Volume 2885

Abstract: 1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: ... ...

Abstract	(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.
Keywords	epidemiology ; incidence ; inflammatory bowel disease ; Crohn’s disease ; ulcerative colitis ; Medicine ; R
Subject code	610
Language	English
Publishing date	2021-06-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED